The U.S. Food and Drug Administration has approved the Xipere eye injection from Bausch Health Companies Inc. and Clearside Biomedical Inc.
The drug (triamcinolone acetonide injectable suspension) is for suprachoroidal use for the treatment of macular edema associated with uveitis, a form of eye inflammation.
Xipere is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, which is the leading cause of vision loss in people with uveitis, said said Joseph C. Papa, CEO of Bausch Health.
Papa expects Xipere to be available during the first quarter of 2022.
The suprachoroidal space is an untapped frontier in eye health. We are proud to be the pioneers in treating serious retinal diseases by implementing this novel, targeted approach. With this approval, we begin a new era in delivering therapies to the back of the eye, said George Lasezkay, Pharm.D., J.D., president and CEO, Clearside. XIPERE is the first commercial product developed by Clearside, the first product approved for injection into the suprachoroidal space and the first therapy approved for macular edema associated with uveitis. Our unique approach now has the potential to positively impact this patient population, which previously had no other treatment options approved for this indication.
Macular edema is the buildup of fluid in the macula, which causes retinal swelling and distorted vision, and if left untreated, may lead to permanent vision loss3. XIPERE is designed to treat macular edema associated with uveitis via suprachoroidal administration using the proprietary SCS Microinjector developed by Clearside. Suprachoroidal administration is an innovative technique for delivering ocular therapies that may facilitate more targeted delivery of therapeutic agents to the retina and choroid.
The SCS Microinjector offers unique access to the back of the eye where sight-threatening disease often occurs. It is designed to provide targeted and compartmentalized delivery and higher proportions of absorption relative to intravitreal injection (IVT)4. Targeted drug delivery via the suprachoroidal space (SCS) may also limit corticosteroid exposure to the anterior segment5 with the potential to reduce the risk of certain adverse events, such as cataracts, intraocular pressure elevation and exacerbation of glaucoma, that are commonly associated with local delivery techniques6.
The safety and efficacy data of XIPERE was demonstrated in multiple clinical studies and its unique suprachoroidal administration approach provides exceptional access and high bioavailability to the posterior segment of the eye, said Steven Yeh, M.D., professor of ophthalmology and director of retinal disease and uveitis, Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, and principal investigator for the XIPERE Phase 3 (PEACHTREE) pivotal study. With the approval of XIPERE, eye care professionals now have a new and innovative treatment option for their patients with macular edema associated with uveitis.
XIPERE Clinical Data The clinical program for XIPERE included the pivotal Phase 3 trial (PEACHTREE), a Phase 3, multi-center, non-interventional extension study (MAGNOLIA), and an open-label safety trial (AZALEA).
The FDA approval of XIPERE was based on results from PEACHTREE, a randomized, multicenter, double-masked, sham-controlled Phase 3 clinical trial of 160 patients with macular edema associated with uveitis. XIPERE is the first and only uveitic macular edema treatment to demonstrate clinical efficacy with a BCVA (Best Corrected Visual Acuity) primary endpoint.
The primary efficacy endpoint was the proportion of patients in whom BCVA had improved by at least 15 letters from baseline after 24 weeks of follow-up. In the trial, a statistically significantly greater proportion of patients treated with XIPERE (47%) achieved at least a 15-letter improvement in BCVA than patients in the control arm (16%, p< 0.01) at Week 247.
The most common adverse reactions reported by greater than or equal to 10% of patients and at a rate greater than control included elevated intraocular pressure and eye pain.
ImportantSafety Information about XIPERE
Indication XIPERE(triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.
IMPORTANT SAFETY INFORMATION Patients should be monitored following injection for elevated intraocular pressure. See Dosage and Administration instructions in full Prescribing Information.
-XIPERE is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
-XIPEREis contraindicated in patients with known hypersensitivity to triamcinolone acetonide or any other components of this product.
-Use of corticosteroids may produce cataracts, increased intraocular pressure, and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses, and should be used cautiously in patients with a history of ocular herpes simplex.
-Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushings syndrome, and hyperglycemia can occur following administration of a corticosteroid. Monitor patients for these conditions with chronic use.
-In controlled studies, the most common ocular adverse reactions were increased ocular pressure, non-acute (14%), eye pain, non-acute (12%), cataract (7%); increased intraocular pressure, acute (6%), cataract (7%), vitreous detachment (5%), injection site pain (4%) conjunctival hemorrhage (4%), visual acuity reduced (4%), dry eye (3%), eye pain, acute (3%), photophobia (3%), and vitreous floaters (3%), and in 2% of patients: uveitis, conjunctival hyperaemia, punctate keratitis, conjunctival oedema, meibomianitis, anterior capsule contraction, chalazion, eye irritation, eye pruritus, eyelid ptosis, photopsia, and vision blurred.
The most common non-ocular adverse event was headache (5%).
-Corticosteroids should be used during pregnancy or nursing only if the potential benefit justifies the potential risk to the fetus or nursing infant.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visitwww.fda.gov/medwatchor call 1-800-FDA-1088.
Please click here for full Prescribing Information.
About Clearside BiomedicalClearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). Clearsides SCS injection platform, utilizing the Companys proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit http://www.clearsidebio.com.
About Bausch + LombBausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. More information can be found at http://www.bausch.com.
About Bausch HealthBausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve peoples lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit http://www.bauschhealth.comand connect with us on Twitterand LinkedIn.
FDA Approves Xipere Eye Injection from Bausch and Clearside - InvisionMag
- Dr. Machida of Second to Creation Awarded Castle Connolly Top Doctor - Digital Journal - May 15th, 2022
- Why Male Clients of This Luxury London Skin Care Clinic Just Love Anti-Wrinkle Treatment - Digital Journal - May 15th, 2022
- More than meets the eye - The New Indian Express - May 1st, 2022
- Is gout reversible? Treatment, management, and more - Medical News Today - May 1st, 2022
- "He sold me a fairytale to fill his own pockets": The horror reality of botched breast implants. - Mamamia - April 18th, 2022
- The Evolution of Looks and Expectations of Asian Eyelid ... - January 21st, 2022
- Expanding Treatment Options for Myasthenia Gravis: Why... : Neurology Today - LWW Journals - January 21st, 2022
- Eyelid Spasms (Eye Twitching or Eye Twitch) | Kellogg Eye ... - January 21st, 2022
- Squints is saved, with help from Animal Shelter Foundation - Tallahassee.com - November 25th, 2021
- The Best Tear Trough and Under-Eye Filler | Dr. Brett ... - November 10th, 2021
- Monolid Eyes: Why They Are Beautiful and More - November 10th, 2021
- Home Page: Journal of Oral and Maxillofacial Surgery - November 10th, 2021
- Dr. Luis Macias and Aesthetic MdR Named Top Plastic Surgeon, Best Surgery Center and Best MediSpa - Business Wire - November 10th, 2021
- Allergan Aesthetics | An AbbVie Company - November 10th, 2021
- Ocular Therapeutix Reports Third Quarter 2021 Financial Results and Business Update - Business Wire - November 10th, 2021
- Aesthetic plastic surgery practice offers the first and only FDA-approved injectable for cellulite - WIBW - October 30th, 2021
- Know the Symptoms of Thyroid or Graves Eye Disease - AARP - October 18th, 2021
- FDA Approves Dextenza for Use in Patients With Ocular Itching Associated With Allergic Conjunctivitis - Pharmacy Times - October 18th, 2021
- Plastic surgeon to celebrities explains every tool she uses - Insider - October 6th, 2021
- BMP4 and inflammation cytokines | JIR - Dove Medical Press - August 21st, 2021
- Dysport 101: Everything to Know About the Fast-Acting Neurotoxin - NewBeauty Magazine - August 21st, 2021
- Elise Hu: The Beauty Ideal - KUAR - August 21st, 2021
- Al Ain's hospital achieves another milestone after performing complex brainstem operation - Gulf Today - June 29th, 2021
- Intense pulse and LLL therapy in meibomian gland dysfunction | OPTH - Dove Medical Press - June 29th, 2021
- Im A Neuro-Ophthalmologist: Here Are 5 Ways To Support Your Eye & Brain Health - mindbodygreen.com - June 12th, 2021
- I Used Makeup to Hide My Asianness Here's Why I Don't Anymore - POPSUGAR Beauty Austrailia - May 31st, 2021
- From ancient Egypt to Beverly Hills: A brief history of plastic surgery - CNN - May 31st, 2021
- How I Learned to Love My Monolids - Vogue - May 31st, 2021
- Plastic Surgery was Buoyed by the Zoom Boom but the End of Social Distancing Offers Patients a New Incentive to Get Started on Procedures, says Dr. J... - May 19th, 2021
- Is Fat Transfer the Future of Anti-Aging? This Expert Says Yes - NewBeauty Magazine - April 22nd, 2021
- The art of gifting tea | Lifestyle Gulf News - Gulf News - April 5th, 2021
- Podcast: In the AI of the Beholder - MIT Technology Review - April 5th, 2021
- Brewed with innovation | Lifestyle Gulf News - Gulf News - April 5th, 2021
- 6 Things You Should Know Before Getting Double Eyelid ... - March 9th, 2021
- Why does Yesung need surgery? Worried fans say Super Junior with you hurt isnt what we want before comeback - MEAWW - February 10th, 2021
- Beauty standards are rooted in whiteness | Opinion | dailytitan.com - The Daily Titan - February 10th, 2021
- Eyelid - Wikipedia - February 1st, 2021
- Surgery for Double Vision in Adults | NYU Langone Health - February 1st, 2021
- Double Vision Causes, Tests, Treatment & Symptoms - February 1st, 2021
- Eye Muscle Surgery - procedure, recovery, blood, pain ... - February 1st, 2021
- Perfect Eyes Ltd | London's Leading Cosmetic Eye Surgeon - February 1st, 2021
- What to Expect After Strabismus (Eye Muscle) Surgery ... - February 1st, 2021
- Plastic Surgery Trends According to Two NYC Experts - DuJour - dujour.com - February 1st, 2021
- These are the Prettiest Idols with Monolid and Double-Eyelids, According to a Plastic Surgeon - Kpopstarz - January 23rd, 2021
- Natural, needle or the knife? How stars from J-Lo to Katie Price got their looks - SamfordCrimson News - The Samford Crimson - January 22nd, 2021
- Here's Everything You Should Know About The K-Pop World - Man's World India - December 28th, 2020
- Expert in Asian Eyelid Surgery Now Operating in Southern California at WAVE Plastic Surgery - PR Web - December 22nd, 2020
- Sharp rise in surgery for dog bites with 3,000 people needing surgery last year - Daily Express - December 21st, 2020
- Types of Double Eyelid Surgery (Don't be Fooled when choosing) - December 13th, 2020
- Plastic Surgery in the Age of the Pandemic: Heres Why Its on the Rise - Vogue.com - December 3rd, 2020
- Update on the latest sports - Newscenter1.tv - November 28th, 2020
- Latest in sports - The Advocate - November 28th, 2020
- BlackRock Throgmorton Trust Plc - Total Voting Rights - Yahoo Finance UK - November 26th, 2020
- Skipping cross the creek - Mount Airy News - November 22nd, 2020
- Double Eyelid: Surgical & Nonsurgical Options, Pictures ... - November 2nd, 2020
- Heres What Idols Go Through When They Get Double Eyelid ... - November 2nd, 2020
- 'You might think the 'fox eye' look is just a beauty trend. This is why it's so triggering.' - Mamamia - October 31st, 2020
- You look Familiar Instagram Face and the De-racialization of Beauty - SWAAY - October 30th, 2020
- World Series 2020: How the Dodgers built their NL champion roster through trades, free agency and the draft - CBS Sports - October 21st, 2020
- East Asian blepharoplasty - Wikipedia - October 2nd, 2020
- The Dark History Behind Double-Eyelid Surgery - October 2nd, 2020
- How Much Does Double Eyelid Surgery (Asian Blepharoplasty ... - September 12th, 2020
- Potential Positive Readout Of Aurinia Pharmaceuticals' Phase 2/3 AUDREY Trial Could Bring Best-In-Class Eye Drops For Dry Eye Syndrome - Seeking Alpha - September 9th, 2020
- PSA: Be Extra Careful When Youre Trying To Open A Vacuum Flask That Is Feeling Uncommonly Tight - The Rakyat Post - August 21st, 2020
- The 'fox eye' beauty trend continues to spread online. But critics insist it's racist - NewsDio - August 18th, 2020
- For black lives to matter, all looks must matter - The Times of India Blog - August 17th, 2020
- The 'fox eye' beauty trend continues to spread online. But critics insist it's racist - CNN - August 12th, 2020
- Covid19 Impact on Asia Pacific Aesthetics Market 2020- Global Trends and Regional Forecast to 2023 - 3rd Watch News - July 15th, 2020
- Fans rally behind Grace Chow and her surgical scars - The Star Online - July 15th, 2020
- The Dark Side of K-Pop Was What Drew Me to the Genre - Allure - April 21st, 2020